Association of subjective cognitive decline with markers of brain pathology in preclinical autosomal dominant Alzheimer's disease

J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):330-332. doi: 10.1136/jnnp-2019-321205. Epub 2019 Dec 24.

Jennifer R Gatchel^{1

2}, Francisco Lopera³, Daniel J Norton¹, Ana Baena³, Edmarie Guzman-Velez¹, Justin S Sanchez⁴, Federico d'Oleire Uquillas⁵, Aaron Schultz⁵, Patrizia Vannini⁶, Arabiye Artola¹, Rebecca E Amariglio^{5

6}, Dorene M Rentz^{5

6}, Pierre N Tariot^{7

8}, Eric M Reiman^{7

8

9

10}, Keith A Johnson^{4

5

6}, Reisa A Sperling^{5

6}, Gad A Marshall^{5

6}, Yakeel T Quiroz^{11

5}

¹ Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA.
² Geriatric Psychiatry, McLean Hospital, Belmont, Massachusetts, USA.
³ Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellin, Colombia.
⁴ Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁵ Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
⁶ Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
⁷ Banner Alzheimer's Institute, Phoenix, Arizona, USA.
⁸ University of Arizona, Tucson, Arizona, United States.
⁹ Arizona State University, Tempe, Arizona, United States.
¹⁰ Neurogenomics Division, The Translational Genomics Research Institute, Phoenix, Arizona, United States.
¹¹ Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA yquiroz@mgh.harvard.edu.

No abstract available

Keywords: amyloid; autosomal dominant Alzheimer’s Disease; preclinical; presenilin-1; subjective cognitive decline (SCD); tau.

Publication types